Although administration of interferon beta to MS patients results in fewer MRI-detectable lesions and fewer relapses, treatment with interferon beta-1 has no effect on disability progression, neither in remitting-relapsing MS [48], nor in secondary progressive MS [49]. Here, IFNB1 is linked to myeloid sarcoma.